Please ensure Javascript is enabled for purposes of website accessibility

How Safe Are Altria and Its Dividend?

By Jeremy Bowman - Updated Apr 2, 2020 at 8:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The tobacco maker already faced challenges before the coronavirus outbreak. Should investors sound the alarm?

In modern investing history, almost no dividend stock has been as reliable as Altria (MO -0.63%), the domestic owner of Marlboro. The tobacco company has raised its dividend 54 times in the last 50 years  . According to Wharton professor Jeremy Siegel, the stock was by far the top performer in the market from 1968-2017, generating an average annual return of 20% annually with dividends reinvested.

It's no surprise then that Altria has been a longtime favorite of dividend investors, and its 9% yield is especially appealing in today's market. In ordinary circumstances, Altria would be considered a rock-solid dividend stock, but the coronavirus outbreak has thrown the normal course of the business around the world off track, and that has had consequences even in the tobacco industry.

A man holding a burning cigarette.

Image source: Altria.

Altria and the coronavirus

You might think that the tobacco sector would be insulated from the upheaval around the coronavirus pandemic as tobacco is generally a recession-proof product. Smoking is addictive, and stressful situations often trigger an increase in habits like smoking. Altria's COVID-19 problems aren't driven by demand issues, though.

First, CEO Howard Willard had tested positive for COVID-19 and took a medical leave of absence as of March 19. CFO William Gifford has temporarily taken over his responsibilities, though it's unclear how long the 56-year-old Altria chief will be out for.  An extended absence could pose a risk to the company at a difficult time.

More concerning was that the company said the same day that it was temporarily suspending manufacturing at its Richmond, Virginia plant, its primary production facility, after learning two employees had contracted the virus.  Altria said it would suspend production for two weeks, though the stoppage could go longer depending on how the coronavirus situation plays out. At the time, Philip Morris USA, the Altria subsidiary that includes Marlboro, had finished goods cigarette inventory equivalent to about two months' supply. In other words, the company could run into problems if its factory is closed for two months or longer. 

Finally, on March 26, the company drew down the entirety of its $3 billion credit facility, following in the footsteps of retailers and other companies struggling to cope with the impact of the coronavirus. Management said it was borrowing that cash "as a precautionary measure to increase its cash position and preserve financial flexibility."  Some of the proceeds will be used to fund its dividend, general corporate purposes, and payments associated with the Tobacco Master Settlement Agreement, the result of the landmark 1998 lawsuit against the tobacco industry.

That decision frees up liquidity, but it also adds to the company's $27 billion debt burden, and weakens a balance sheet that has already been inflated by goodwill and intangible assets.

Is Altria's dividend safe?

Prior to the coronavirus outbreak, Altria was facing considerable challenges. To diversify away from cigarettes, which have been in decline for years, the company made two bold moves at the end of 2018. It took a 35% stake in Juul Labs, the leading maker of e-cigarettes, for $12.8 billion, and acquired a 45% stake in Canadian marijuana grower Cronos Group (CRON -6.45%), for $1.8 billion. Neither investment has fared well. It has twice been forced to write down the value of its Juul investment after regulatory scrutiny led Juul to stop making most of its flavored pods and cease most advertising. Altria now values its stake in Juul at just $4.2 billion. Shares of Cronos, meanwhile, have lost about 50% of their value since Altria made that deal as marijuana stocks have largely underperformed since then.

Right now, the biggest risk for the company is that its Richmond plant will remain closed past the two weeks the company had allotted, which end April 2. If the plant remains closed for several weeks longer, that could provoke a run on cigarettes and lead to shortages before its estimated two-month supply is exhausted. Given that the coronavirus outbreak has not yet peaked, Altria is likely to continue the plant closure, though investors should expect an announcement on that soon.

The silver lining for investors here is that these risks appear to be priced into the stock. Altria's dividend yield has soared to 10-year highs, and the stock price is at a five-year low. Cigarette consumption isn't about to disappear, and even an extended closure at the Richmond facility shouldn't impact the company's ability or commitment to paying its dividend, as management has already shown it's willing to borrow in order to fund it. 

While Altria stock could still head lower in the coming weeks, income investors may want to take advantage of its sky-high yield today.

Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altria Group, Inc. Stock Quote
Altria Group, Inc.
$45.45 (-0.63%) $0.29
Cronos Group Stock Quote
Cronos Group
$3.19 (-6.45%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.